CrownCast

What if the next breakthrough in cancer treatment isn't a pill or infusion, but a precisely targeted radioactive payload that hunts down tumor cells like a guided missile? In this Smart Biotech Scientist Podcast episode, Dr. David Brühlmann speaks with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, about the radiopharmaceutical revolution transforming oncolog...

When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely. In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi S...

Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Development and Bryan Miller, Director of Scientific and Technical Operations about leveraging the UK’s vibrant ecosystem of cutting-edge technologie...

As cancer research progresses rapidly, obtaining high-quality biospecimens has grown increasingly important for making significant breakthroughs. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sadaf Malik, Senior Director, Head US Sales (Biobank and Biomarker) about how superior biospecimens can drive advancements in oncology...

As the landscape of drug discovery evolves, breakthrough technologies like organoids are gaining traction for their potential to revolutionize how new treatments are developed. In this episode of CrownCast, Jonny McMichael, Vice President at Crown Bioscience, and Leo Price, a member of Crown Bioscience’s Scientific Advisory Board, shed light on organoids' growing role in drug development. With ins...

In the relentlessly evolving landscape of drug discovery, modern technologies and groundbreaking methods are going beyond animal testing to ensure a more human-centric, efficient, and improved approach in terms of reliability. It's a journey that promises a more efficient future for pharmaceutical companies and, ultimately, patients worldwide. Dive into the details with industry leader Professor T...

In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia d...

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that resistance often leads to...

Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending project...

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed b...

Are you ready to understand the seismic shifts in the CRO (Contract Research Organization) industry? Join Johnny McMichael, VP of Client Experience and Enablement at Crown Bioscience, and Alex Slater, Chief Business Officer, as they delve into how strategic partnerships and innovation are redefining drug discovery and development. This video is a must-watch for executives navigating the complexiti...